- In January 2025, Medipan GmbH extended the shelf life of its RIA kits, including SELco TSH Rapid, SELco Tg 1 Step, and SELco Calcitonin, by two weeks. This extension, through optimized production, enhances flexibility and improves planning for customers, solidifying Medipan’s competitive position by offering added value and efficient inventory management in the RIA market
- In December 2022, Medipan launched the SELco TRAb human 1 step, a streamlined RIA for detecting thyroid-stimulating hormone receptor antibodies (TRAb). This innovation reduces incubation time to 120 minutes, improving laboratory efficiency and turnaround times. It strengthens Medipan’s position by enhancing diagnostic convenience and speeding up processes in clinical settings
- In October 2022, DiaSorin S.p.A. acquired Luminex Corporation to enhance its molecular diagnostics and life sciences portfolio. Luminex’s expertise in multiplexing technologies opens opportunities for cross-platform RIA development, particularly for sensitive applications such as hormone testing, positioning DiaSorin as a key player in precision diagnostics
- In July 2020, Svar Life Science and DIAsource ImmunoAssays transferred Svar’s RIA portfolio, including assays for peptide hormones, to DIAsource. This ensures the continued availability of critical diagnostic products, particularly in tumor marker testing and diabetology, boosting DIAsource’s market presence in these specialized areas
